A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy

© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

¹University of Arizona, Tucson, Arizona;
²Warren Alpert Medical School of Brown University, Providence, Rhode Island;
³Northwestern University, Evanston, Illinois;
⁴Geisel School of Medicine at Dartmouth, Hanover, New Hampshire;
⁵Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
⁶Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands;
⁷TUM School of Medicine, Technical University of Munich, Munich, Germany;
⁸Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;
⁹Cancer Imaging, Prostate Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
¹⁰Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
¹¹Rostock University Medical Center, Rostock, Germany;
¹²Novartis Pharmaceuticals Corporation, Indianapolis, Indiana;
¹³Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
¹⁴Novartis Pharmaceuticals Corporation, St. George, Utah;
¹⁵Advanced Accelerator Applications, Geneva, Switzerland; and
¹⁶Mayo Clinic, Rochester, Minnesota

For correspondence or reprints, contact Phillip H. Kuo (pkuo{at}email.arizona.edu).